These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6461763)

  • 1. Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer.
    Furr BJ; Nicholson RI
    J Reprod Fertil; 1982 Mar; 64(2):529-39. PubMed ID: 6461763
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat.
    Nicholson RI; Kéri G
    Tumour Biol; 1992; 13(1-2):44-50. PubMed ID: 1534181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the hormone dependency of DMBA-induced rat mammary tumors with reference to the effect of tamoxifen.
    Inui K; Morimoto T; Komaki K; Sonoo H; Monden Y
    Jpn J Surg; 1988 May; 18(3):284-90. PubMed ID: 3136267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a new analogue of luteinizing hormone releasing hormone, ICI 118630, on the growth of rat mammary tumours [proceedings].
    Nicholson RI; Finney EJ; Maynard PV
    J Endocrinol; 1978 Nov; 79(2):51P-52P. PubMed ID: 366064
    [No Abstract]   [Full Text] [Related]  

  • 6. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
    Nicholson RI; Maynard PV
    Br J Cancer; 1979 Mar; 39(3):268-73. PubMed ID: 380618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour potential of a new luteinizing hormone releasing hormone analogue, ICI 118630.
    Nicholson RI; Walker KJ; Maynard PV
    Eur J Cancer (1965); 1980; Suppl 1():295-9. PubMed ID: 6459236
    [No Abstract]   [Full Text] [Related]  

  • 9. Pre-clinical and clinical treatment of breast cancer with antiprogestins.
    Klijn JG; Setyono-Han B; Sander HJ; Lamberts SW; de Jong FH; Deckers GH; Foekens JA
    Hum Reprod; 1994 Jun; 9 Suppl 1():181-9. PubMed ID: 7962463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog.
    Johnson ES; Seely JH; White WF; DeSombre ER
    Science; 1976 Oct; 194(4262):329-30. PubMed ID: 823643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
    Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
    Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Luteinizing hormone-releasing hormone agonists for treatment of breast cancer].
    Gez E; Kovner F
    Harefuah; 1990 Jun; 118(11):655-8. PubMed ID: 2143745
    [No Abstract]   [Full Text] [Related]  

  • 14. Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer.
    Lombardi P; Florio S; Pagnini U; Crispino A; Avallone L
    J Vet Pharmacol Ther; 1999 Feb; 22(1):56-61. PubMed ID: 10211718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat.
    Hartmann RW; Schönenberger H; Wrobel KH
    J Cancer Res Clin Oncol; 1982; 103(3):241-54. PubMed ID: 6288725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of medroxyprogesterone acetate on DMBA-induced rat mammary carcinoma and on immunological reactivity.
    Spreafico F; Filippeschi S; Malfiore C; Noseda S; Falautano P; Serraglia N
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):45-51. PubMed ID: 6211360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione.
    Brodie AM; Marsh D; Brodie HJ
    J Steroid Biochem; 1979 Apr; 10(4):423-9. PubMed ID: 109701
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemoendocrine therapy in advanced breast cancer.
    Kiang DT; Kennedy BJ
    Breast Cancer Res Treat; 1981; 1(2):105-9. PubMed ID: 6816316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Redding TW; Schally AV
    Prog Clin Biol Res; 1988; 262():217-40. PubMed ID: 2897695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.